Bausch & Lomb is suspending US sales of its ReNu MoistureLoc solution after CDC findings that the solution may be responsible for eye infections that can potentially lead to loss of sight. The stock is now careening southward on the predictable downgrades. Ah, the opportunities for bad puns:
- We didn't see it coming.
- Even though we had our eye on the stock.
- Still too soon to tell if pulling the product was a bad solution.
Also, we're using the stuff RIGHT NOW, so if DealBreaker goes dark, we've gone completely blind and it's B&L's fault.
JPMorgan Cuts Bausch & Lomb to Underweight [newratings.com]
B&L Plunges in Pre-market [IBD]
Posted by junkies @ c! Media, Apr 11, 2006 8:51PM
we saw trouble looming at $70 -- told clients -- and rode it down to damn near $40.
get shorty, stupid.